There are no conflicts of interest the authors wish to disclose. Participants in both sample sets who developed a metachronous adenoma had significantly higher ALIs in their baseline adenoma than participants who remained adenoma-free. In the replication set, the adjusted odds for metachronous adenoma increased 1.46 for each 10% increase in ALIs (p=0.03). A best-fit algorithm-based cutpoint of 22.4% had specificity of 75.0% and positive predictive value of 70.0% for metachronous adenoma development. A larger population of ALDH1A1-expressing cells in an adenoma is associated with a higher risk for metachronous adenoma, independent of adenoma size or histopathology. If confirmed, ALDH1A1 has potential as a novel biomarker in risk assessment and as a potential stem-cell target for chemoprevention.
Introduction
Colorectal adenoma is a well-known precursor to colorectal carcinoma, and removal is associated with a reduced incidence of colorectal cancer (1) (2) (3) (4) (5) (6) . Among patients who form an adenoma, risk of developing future metachronous colorectal neoplasia in another site in the large bowel, commonly termed "recurrence", is based on the clinical-pathologic features of the patient and the presenting adenoma. Subsequent risk is higher in patients who present with clinical features of three or more adenomas or at least one adenoma that is large (≥ 1 centimeter) or has histopathologic features of villous architecture or high-grade dysplasia, termed an advanced adenoma (6) (7) (8) .
While colorectal adenomas are relatively common in the general population, with a prevalence of 20-30% over age 50 years, most are small lesions with low-grade dysplasia, of which it is estimated that only approximately 5-10% would progress to cancer (6) . As a result, yields from endoscopy-based short-interval surveillance for three to five years are dominated by the detection and removal of small, low-risk adenomas with little discernible clinical significance. These results challenge the cost-effective delivery of endoscopic follow up and the overall clinical value of screening and surveillance for prevention of colorectal cancer in the average-risk population (9) .
While controversial, cancer cells with stem cell-like properties in solid tumors are thought to comprise a subpopulation with self-renewing and multi-potent differentiation properties that are functionally analogous to adult stem cells (10) (11) (12) . markers in a broad spectrum of organ-specific tumors including colorectal carcinoma (13) (14) (15) (16) (17) (18) (19) (20) (21) .
Stem-like cells have been reported among premalignant colorectal cells of patients (21) (22) (23) (24) (25) (26) (27) and in animal models of colorectal tumorigenesis (28, 29) . However, in contrast to the large number of published studies on subpopulations of cells with tumorinitiating properties in cancers, there is a paucity of information about such cells in benign neoplasms such as colorectal adenoma, including their clinical-pathologic associations and clinical relevance.
Numerous expression biomarkers for identifying stem cells and cells with stemlike properties have been described. (10, 11, 13, 30, 31) These include the product of the aldehyde dehydrogenase isoform 1A1 (ALDH1A1) gene, a member of the ALDH superfamily on chromosome 9q21.13 (32) (33) (34) (35) (36) (37) (38) . This superfamily of proteins catalyzes the irreversible oxidation of a range of endogenous and exogenous intracellular aldehydes to their corresponding carboxylic acids, and metabolizes aldehyde intermediates for synthesis from retinol toretinoic acid, a modulator of cell proliferation. These enzymes also metabolize folate; a micronutrient that is important in various cellular functions in which deficiency has been associated with risk of colorectal tumors (36) . The enzymatic activity and expression of ALDH1A1 have been shown to mark subpopulations of colorectal epithelial cells with stem-like properties (10, 13, 20, 23, 39, 40 extensively to evaluate stem-like cells in colorectal tumors (10, 13, 20, 23, 39, 40) as well as numerous other tumor types.
In this study, we hypothesized that stem-like cells in colorectal adenoma could be related to clinical-pathologic characteristics and the development of metachronous adenoma. We therefore characterized the population of ALDH1A1-expressing cells as an indicator of 'stem-cell burden' in baseline adenoma from an exploratory subset and a replication subset of placebo-treated participants with available tissues from two completed chemoprevention trials with protocol driven follow-up colonoscopy (41, 42) .
Materials and Methods

Exploratory and replication study groups
Two sets of specimens were obtained from participants randomized to the placebo arms of the Wheat Bran Fiber Trial (42) or Ursodeoxycholic Acid Trial (41) at
The University of Arizona for the prevention of metachronous colorectal adenomas.
Characteristics of these exploratory and replication sample subsets are presented in Table 1 . Age, gender, and adenoma clinical characteristics (size and location) were obtained by review of colonoscopy and pathology reports in medical records. Tubular, tubulovillous, or villous architecture and grade of dysplasia in routine histopathologic slides prepared from tissue blocks were determined by central review by gastrointestinal pathologists participating in the conduct of the trials. In total, 65 participants (85.5%) in the replication set had one baseline adenoma, and the other 11 (14.5%) had at least two synchronous baseline adenomas, with two of these 11 participants having a third baseline adenoma. These subjects with multiple adenomas permitted within-participant comparisons of adenoma ALDH1A1 levels. In addition, among the 76 subjects, four participants had two blocks available from the same adenoma, permitting a limited intra-adenoma comparison.
The clinical trial protocols, including retrieval and subsequent laboratory evaluation of specimens obtained at colonoscopy, were reviewed and approved by The 
Immunohistochemistry for ALDH1A1 expression
Expression of the stem cell marker ALDH1A1 was evaluated by immunohistochemistry, as reported previously (43) . The mouse monoclonal antibody (Catalog #611195, BD Biosciences, San Diego, CA) identified cells that formed spheroids in vitro and successful xenografts in vivo in a previous study (40) . Manual immunohistochemistry was used for the exploratory set of cases. For evaluation of the larger replication set, the immunohistochemistry procedure was automated on an IntelliPATH FLX slide stainer (Biocare Medical, Concord, CA). Reagents, steps and conditions were identical to those used for the exploratory set. Topographical evaluation of the upper regions of adenoma glands in the replication set was done in an exploratory analysis to provide ALDH1A1 labeling indices for the upper third of glands that was included in the evaluation of the exploratory set of adenomas. The oriented areas, when present, of each specimen that included both the surface epithelium and the muscularis mucosae and/or deep lamina propria visible in its whole slide image were demarcated for image analysis of the upper thirds of the glands.
Morphometric and image analysis of ALDH1A1 expression
Statistical analysis
Demographic and clinical characteristics of participants and pathologic characteristics of adenomas were analyzed. In the exploratory set, comparison of ALDH1A1 labeling indices (ALIs) across compartments within the same participant was performed using Wilcoxon signed rank tests. Comparisons in specimens from participants with and without a subsequent metachronous adenoma were performed using Wilcoxon rank sum tests. In the replication set, logistic regression with a likelihood ratio test was used to assess the statistical significance of the relationship between ALIs and subsequent adenoma detection at follow-up colonoscopy. Therefore, all participant-level analyses were performed using both the mean and the maximum ALI value for all adenomas of each participant. We also evaluated the relationship between ALIs and clinical-pathologic covariates using logistic regression, including characteristics of the advanced or non-advanced adenomas at baseline. In addition, we used a classification and regression tree (CART) analysis based on binary recursive partitioning to explore an optimal cutpoint for ALIs to maximize the reduction in impurity and best classify the subject for metachronous adenoma status at follow-up.
Results
Exploratory set: ALDH1A1 expression in baseline adenomas and subsequent metachronous adenoma status. For adenomas in the exploratory set ( Figure 1C-F There were no significant associations between ALIs of the adenomas and participant age or gender (data not shown). We observed a non-significantly higher mean ALI among proximal adenomas compared to distal adenomas in the left colon and rectum (22.1% versus 16.0%, p=0.09). Of note, at the individual adenoma level there were no differences in ALIs between non-advanced and advanced adenomas (mean ALDH1A1 of 16.3% for non-advanced versus 18.5% for advanced, p = 0.45, Figure 3 ).
High and low ALIs were found in both advanced and non-advanced adenoma. The ALDH1A1 LIs in the 11 participants with more than one adenoma (i.e. synchronous baseline adenomas) were similar in 9 participants and discordant in 2 ( Figures 3 and 4 and Supplemental Figure 2) , with an overall intraclass correlation coefficient of 0.67.
Replication set: ALDH1A1 expression in baseline adenomas and subsequent metachronous adenoma status. As was found in the exploratory set using topographical determination of ALIs, subjects who developed an adenoma at follow-up had a significantly higher mean ALI (Figure 4) increase in ALI. The increased odds for adenoma development with ALDH1A1 levels remained significant even after adjustment for age and sex and inclusion of an indicator variable for advanced status of the adenoma at baseline (adjusted OR=1.46, 95% CI 1.04-2.06, p=0.03). When we restricted our analyses to those subjects in whom the adenoma could be confidently oriented to assess the upper third of the glands (n=50 of 76), we found that the ALDH1A1 labeling across the whole adenomas was highly correlated with the upper glands. The correlation at the participant-level between
[mean] whole and oriented ALDH1A1 values was 0.88. For metachronous adenoma risk, the magnitude and direction of the adjusted association remained (adjusted OR=
1.95, p=0.26).
Replication set: ALDH1A1 expression in baseline adenomas as a predictor of metachronous adenoma development. In an effort to identify a potentially useful ALI cut-point that could be used for further investigation as a tissue biomarker for predicting metachronous adenoma risk in high-risk adenoma patients, we performed a data-driven classification and regression tree (CART) analysis. The splitting algorithm identified an ALI cutoff point of ≥22.4% ALDH1A1-expressing cells as an optimal threshold for classifying risk of metachronous adenoma in our sample ( Table 2 ). The frequency of metachronous adenomas was 75.0% for ALIs above this CART cut-point, and 39.6% for ALIs below the cut-point (OR = 4.58, 95% CI 1.63-12.86; p value=0.004). By contrast, the metachronous adenoma rate was 63.6% for ALIs at or above the mean ALI (18.9%), We also assessed the sensitivity and specificity of ALI for the development of a metachronous adenoma using a cutoff of 0.5 for the predicted probability. Incorporating ALI increased both the sensitivity and specificity over age, male gender and advanced status of adenomas, especially when ALDH1A1 expression was treated as a binary variable based upon the CART cut-point of ≥22.4% or <22.4% (Table 3) . For the final model with the binary ALI cut-point for ALDH1A1 expression, sensitivity for development of an adenoma at follow-up among the high-risk cohort was 52.5% with specificity of 75.0%, and positive and negative predictive values of 70.0% and 58.7%, respectively (Table 3) .
Discussion
We report for the first time that the fraction of ALDH1A1-expressing putative stem-like cells in colorectal adenoma epithelium is correlated among synchronous adenomas in individual patients, and that the presence of a larger subpopulation of these adenoma stem-like cells is associated with increased risk for the patient to have a metachronous adenoma at another location in the large bowel at follow-up. Of note, the association between percentage of ALDH1A1-expressing adenoma cells and risk of a metachronous adenoma is independent of both the adenoma and clinical characteristics previously reported to be associated with increased risk (i.e. villous architecture, high-grade dysplasia, and size of the baseline adenoma, and age and male sex of the study subjects). Our findings raise the possibility that a larger stem-like We confirmed previous reports of approximately 6 .0% ALDH1-positive cells in non-neoplastic crypts and approximately 30% in adenomatous glands, representing a 5-to 6-fold increase in ALDH1 expression with progression to premalignancy (23) . We found similar mean ALDH1A1 labeling percentages: 6.3% in non-neoplastic crypts of participants who all had at least one adenoma, and 31.7% in adenomatous glands.
Although our sample size is small, we found for the first time the presence of highly correlated intra-adenoma, intra-participant ALDH1A1 labeling indices in four participants who had at least two blocks from the same adenoma, indicating intra-tumoral homogeneity within different regions of each tumor. Of even greater interest, we also observed strong inter-adenoma/intra-participant correlation in 11 patients with multiple adenomas ( Figure 3 and 4 and Supplementary Figure 2) . These results support previous findings suggesting that cancer stem cells and adenoma stem-like cells reside in a niche microenvironment (30, 45, 46) . The mechanisms leading to the observed correlated deregulation of the stem cell subpopulations and their overgrowth in synchronous adenomas remain to be explained. This concept of a niche effect is consistent with previous work on the concept of field defects in carcinogenesis and supports the occurrence of a generalized intra-patient predisposition to a stem-like cell niche that participates in adenoma development. previous reports (23, 34, 39) , in contrast to results found with other putative stem cell markers such as CD44 and CD133 (23) .
Limitations include our relatively small sample sets and the focus in the replication sample set on high-risk participants for whom adequate pathology material was available as convenience samples in the specimen repository. Further, while our data are suggestive of higher ALDH1A1 LIs in proximal adenomas, which have a higher propensity for 'recurrence', proximal adenomas commonly occur along with distal adenomas. These were often collected in the same specimen vial after polypectomy, thus limiting our ability to identify a larger, purely proximal population of adenomas.
In conclusion, our study shows for the first time that ALDH1A1 expression in a baseline adenoma is an independent risk factor for development of a metachronous adenoma. Our findings suggest that the assessment of ALDH1A1 expression is Table 1 . Baseline characteristics of study participants with baseline adenoma specimens in the exploratory and replication sets Exploratory set (n = 20 subjects) 1 Replication set (n = 76 subjects) 2 Age in years, mean ± SD 66.0 ± 9.7 64.9 ± 9.3 
